NewEdge Wealth LLC Acquires 949 Shares of Sanofi (NASDAQ:SNY)

NewEdge Wealth LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 4.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,319 shares of the company’s stock after purchasing an additional 949 shares during the quarter. NewEdge Wealth LLC’s holdings in Sanofi were worth $1,110,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in SNY. Rise Advisors LLC increased its holdings in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after purchasing an additional 251 shares in the last quarter. SRS Capital Advisors Inc. increased its holdings in Sanofi by 289.1% in the first quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock worth $25,000 after purchasing an additional 344 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in Sanofi in the third quarter worth approximately $26,000. Fairfield Bush & CO. acquired a new stake in Sanofi in the first quarter valued at approximately $26,000. Finally, Indiana Trust & Investment Management CO acquired a new stake in Sanofi in the third quarter valued at approximately $27,000. 10.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $46.24 on Tuesday. The firm has a market capitalization of $116.97 billion, a P/E ratio of 19.59, a P/E/G ratio of 1.72 and a beta of 0.61. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. The stock’s 50-day simple moving average is $47.59 and its two-hundred day simple moving average is $48.76. Sanofi has a twelve month low of $42.63 and a twelve month high of $57.82.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a return on equity of 27.47% and a net margin of 12.56%. The business had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. As a group, equities analysts anticipate that Sanofi will post 4.16 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Stockholders of record on Friday, May 10th will be issued a $1.478 dividend. This is a boost from Sanofi’s previous annual dividend of $1.38. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SNY. Morgan Stanley initiated coverage on Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.